Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Key Points

• The aim is to compare the safety profiles of ocrelizumab and rituximab in treating multiple sclerosis.
• Utilized real-world data to assess medication safety.
• Analyzed adverse event reports associated with each treatment.
• Compared outcomes based on safety metrics.
• Identified differences in adverse event frequencies between the two therapies.
• Provided insights on the tolerability of ocrelizumab compared to rituximab.

Abstract